MedTrace Logo

Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant

NCT05416190 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-06-21

No results posted yet for this study

Summary

The aim is to assess the effect of injectable anticoagulants (unfractionated heparin (UFH), low molecular weight heparins (LMWH), fondaparinux, danaparoid, argatroban) on lupus anticoagulant testing assays over broad anti-Xa activity ranges and to establish their potential for causing false-positive or false-negative results.

Conditions

  • Antiphospholipid Syndrome
  • Anticoagulant Drugs

Interventions

DIAGNOSTIC_TEST

Lupus anticoagulant testing

The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Laurie TALON · University Hospital, Clermont-Ferrand

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-02
Primary Completion
2024-05-21
Completion
2024-05-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05416190 on ClinicalTrials.gov